Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis

Nephron - Clinical Practice

Volumn 100, Issue 3, 2005, Pages

  Charytan, Chaim ^a   Qunibi, Wajeh ^b   Bailie, George R ^c,d,e  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d Albany Nephrology Pharmacy ANephRx Group   (United States)

^e Nephrology Pharmacy Associates   (United States)

Author keywords

Anemia; Chronic kidney disease; Intravenous iron; Iron sucrose; Oral iron; Pre dialysis

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; ASTHMA; BRONCHOSPASM; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URTICARIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA; CHRONIC DISEASE; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY DISEASES; MALE; MIDDLE AGED; SUCROSE;

EID: 20944449485     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085049     Document Type: Article

References (27)

1. Foley RN, Parfrey PS, Morgan J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335.
2. Levin A, Thompson CR, Ethier J, et al: Left ventricular mass index in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134.
3. Schafer GE, Rehbein C, Stiegler T, et al: Renal anemia and its hemodynamic response. Clin Nephrol 2002;58(suppl 1):S52-S57.
4. Ifudu O, Uribarri J, Rajwani I, et al: Low hematocrit may connote a malnutrition/inflammation syndrome in hemodialysis patients. Dial Transplant 2002;31:845-847, 878.
5. Xue JL, St. Peter WL, Ebben JP, et al: Anemia treatment in the pre-end-stage renal disease period and associated mortality in elderly patients. Am J Kidney Dis 2002;40:1153-1161.
6. Abramson JL, Jurkovitz CT, Vaccarino V, et al: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC Study. Kidney Int 2003;64:610-615.
7. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Kidney Diseases. Update 2000. Available at www.kdoqi.org.
8. Chow F, Briganti E, Kerr P, Chadban S, Zimmet P, Atkins R: Health-related quality of life in Australian adults with renal insufficiency: A population-based study. Am J Kidney Dis 2003;41:596-604.
9. McClellan W, Flanders W, Langston R, Jurkovitz C, Presley R: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol 2002;13:1928-1936.
10. Wilson P, Culleton B: Epidemiology of cardiovascular disease in the United States. Am J Kidney Dis 1998;32(suppl 3):S56-S65.
11. Silverberg DS, Wexler D, Blum M, et al: The effect of correction of anemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-146.
12. Silverberg DS, Wexler D, Blum M, et al: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-1744.
13. Silverberg DS, Iaina A, Peer G, et al: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure in patients not receiving dialysis. Am J Kidney Dis 1996:27:234-238.
14. Stoves J, Inglis H, et al: A randomized study of oral vs. intravenous supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001;16:967-974.
15. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G: Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physns India 2003;51:170-174.
16. Trivedi HS, Brooks BJ: Erythropoietin therapy in pre-dialysis patients with chronic renal failure: Lack of need for parenteral iron. Am J Nephrol 2003;23:78-85.
17. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:13.
18. Portoles J, Torralbo A, Martin P, et al: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997;29:541-548.
19. Wingard RL, Parker RA, Ismail N, Hakim RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995;25:433-439.
20. Nissenson AR, Berns JS, Sakiewicz P, et al: Clinical evaluation of heme iron polypeptide: Sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 2003;42:325-330.
21. Nissenson AR, Charytan C: Controversies in iron management. Kidney Int 2003;87(suppl): S64-S71.
22. Magana L, Dhar SK, Smigh EC, Martinez C: Iron absorption and utilization in maintenance hemodialysis patients: Oral and intravenous routes. Mount Sinai J Med 1995;51:180-183.
23. Lomaestro BM, Bailie GR: Absorption interactions with fluoroquinolones: 1995 update. Drug Saf 1995;12:314-333.
24. Warady BA, Kausz A, Llerner G, et al: Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004 (Epub).
25. Bailie GR, Lane PL, Clark JA, Stang PE, Lane CE: Safety surveillance of intravenous iron preparations - relative rates of hypersensitivity reactions reported in the USA (abstract). J Am Soc Nephrol 2003;14:458A.
26. Van Wyck DB, Cavallo G, Spinowitz BS, et al: Safety and efficacy of intravenous iron in patients sensitive to iron dextran: North American Clinical Trial. Am J Soc Nephrol 2000;36:88-97.
27. Roe DJ, Harford AM, Zager PG, et al: Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agents. Am J Kidney Dis 1996;28:855-860.